• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ATXI

ATXI

Avenue Therapeutics, Inc.

OTCHealthcareBiotechnologyUS

USD0.35

+0.05 (+17.78%)

Rating:C+

Company Profile

CEO

Alexandra MacLean

IPO Date

2017-06-27

Sector

Healthcare

Industry

Biotechnology

Exchange

OTC

Country

US

Market Metrics

Open

$0.30

Prev. Close

$0.30

Day Low

$0.30

Day High

$0.35

52W Low

$0.15

52W High

$0.97

Market Cap

$0.00B

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

19.1%

Avg Negative

40.2%

Avg Neutral

40.8%

News Feed

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

GlobeNewsWire·6/14/2021·↑ positive

Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?

Zacks Investment Research·4/19/2021·↓ negative

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI

PRNewsWire
·4/13/2021
·↓ negative

ATXI Stock: Over 15% Decrease Pre-Market Explanation

Pulse2·4/13/2021·↓ negative

Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol

GlobeNewsWire·4/13/2021·↓ negative

ATXI Stock: Over 15% Increase Pre-Market Explanation

Pulse2·4/12/2021·↑ positive

Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis

GlobeNewsWire·12/18/2020·↑ positive

Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2

Yahoo·8/17/2020·↓ negative

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Yahoo·8/14/2020·↑ positive

What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?

Yahoo·8/4/2020·↓ negative